ÂÜÀòÂÒÂ×

Ryan Lynch is the VP of Finance at Kelonia Therapeutics. Ryan has over fifteen years of experience in the finance and accounting industry. Ryan began their career at PricewaterhouseCoopers as an Experienced Associate and then moved to Network Engines where they became the SEC Reporting Accountant and Manager of Accounting. In 2012, they became the Accounting Manager at VetCor before becoming a consultant at Sarepta Therapeutics in 2013. Ryan returned to Network Engines in 2014 as Senior Manager of Financial Reporting before moving to Concert Pharmaceuticals in 2016 as Associate Director of Financial Reporting. In 2017, they were promoted to Senior Director of Corporate Controller and held this position until 2019 when they joined Morphic Therapeutic as their Sr. Director, Corporate Controller. Ryan has been with Kelonia Therapeutics since December 2019.

Ryan Lynch has a Master of Science in Accounting from the University of Massachusetts, Amherst and a Bachelor of Business Administration in Accounting from the University of Massachusetts at Amherst - Isenberg School of Management.

Ryan Lynch reports to Kevin Friedman, Chief Scientific Officer & President. Ryan Lynch works with Jennifer Curry - VP, HR, Connor Dobson - Scientist II, and Jose Sanabria - Principal Associate Scientist.